Cancer study focuses on the intricate association between aggravation and the growth of cancer, which reveals intricate relationships between malignant cells, cytokines, and pro-inflammatory cells inside the tumor microenvironment (TME). The molecular and cellular processes underpinning this interaction and its consequences for cancer treatment are thoroughly reviewed in this chapter. Inflammation has pro- as well as anti-tumorigenic actions, playing two distinct functions in cancer. Pro-tumorigenic inflammation facilitates the origin, growth, and spread of tumors through processes like inducing genome instability, enhancing blood vessel development, and suppressing tumor-fighting defenses. Inflammatory cells including neutrophils, T lymphocytes, and macrophages as well as signaling pathways like STAT3 and NF-κB are important participants in this mechanism. Furthermore, irritation may stimulate anti-tumorigenic effects by encouraging tissue healing, immunological monitoring, and regression of tumors. Using the immune system’s attack against tumors has the potential to lead to the creation of new treatment approaches. Inflammatory management has become an intriguing possibility for cancer treatment. Treatment results may be enhanced by anti-inflammatory medications, immunotherapy procedures, and a combination of treatments that influence the inflammatory TME. But there are still issues to be resolved, like resistance to treatment and variations in inflammation among cancer kinds. Ultimately, comprehending the intricate relationship between inflammation and the advancement of cancer offers new perspectives on methods of therapy and emphasizes the significance of tailored medicines in the fight against cancer. It is highly promising that more studies in this area will help us fight disease and enhance outcomes for patients.